SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing a dramatic surge, fueled by impending Chinese export restrictions on silver and strong community sentiment that years of market suppression are finally breaking. Investors are actively debating if this is a true price discovery for silver as a critical industrial and monetary metal or an unsustainable bubble, with many anticipating significant price appreciation as de-dollarization concerns grow.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending because of its incredibly active and conviction-driven community, which passionately champions the "OG meme" narrative of Rage Comics. This dedicated base is continuously building out the ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into the crypto space. The community views RAGE as significantly undervalued, expressing strong belief in its potential for substantial long-term growth, with many discussing a target of "billions" or "51B."

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

Alpha Capital Acquisition Co (ASPC) is trending due to an extraordinary surge in trading volume and price, sparking intense community discussion about a potential short squeeze. Fueling the conversation are mentions of its low float and extremely high borrow rates, leading many to speculate on significant further upward movement, while others express caution regarding its volatile nature.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is drawing significant attention for its Gemini-II APU, which proponents laud for its ultra-low power and compute-in-memory architecture, seeing it as a game-changer for edge AI in defense and space applications. While many anticipate further catalysts from ongoing military partnerships and upcoming LLM benchmarks, the community also shows caution regarding its long-term commercial adoption and recent insider transactions.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending amidst a historic surge in silver prices, driven by an acute global supply deficit and strong industrial demand. The community expresses significant frustration over the stock's current lagging performance, attributing it to market manipulation, but remains highly optimistic for an eventual explosive 'catch-up' rally. Long-term bullish sentiment is fueled by expectations of sustained physical demand and potential catalysts like the Jerritt Canyon update.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is actively trending as the community anticipates a monumental silver squeeze, driven by a global supply shortage and escalating industrial demand from sectors like EVs and AI. Investors are highlighting a belief that decades of price suppression are finally breaking, leading many to advocate for physically-backed options like PSLV over traditional paper silver ETFs. This situation is further amplified by macro concerns about currency debasement and inflation, positioning silver for a significant revaluation.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

YEE Crypto is trending with strong upward momentum, fueled by an enthusiastic community deeply invested in a "9-year prophecy" narrative. Many believe it represents the resurgence of "OG memecoin culture" on Ethereum, aligning with a broader "ETH season" and attracting significant community conviction through consistent dip buying.

Hecla Mining Co. engages in the provision of precious and base metals. It operates through the following segments: Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Other. The company was founded by Amasa B. Campbell, Patsy Clark, and John Finch on October 14, 1891 and is headquartered in Coeur d'Alene, ID.

Hecla Mining Co.

Hecla Mining (HL) is trending amidst a booming silver market, fueled by severe global supply shortages and surging industrial demand driving spot prices dramatically higher. Despite community concerns over perceived market manipulation, many anticipate HL and other miners to eventually "explode higher" and significantly outperform silver, especially given Hecla's upcoming production increases and exploration catalysts.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending following a historic rally to new all-time highs, reflecting broad market concerns over geopolitical tensions and a weakening dollar. Community discussions highlight a significant rotation of capital from crypto into precious metals, with many seeing gold as a crucial hedge against ongoing economic uncertainty and anticipated monetary easing. Investors are actively debating the sustainability of this 'generational move' versus the potential for a near-term correction amidst overbought conditions.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power (SMR) is experiencing extreme volatility and divided investor sentiment following a significant price correction, driven by concerns over ongoing institutional share sales and an upcoming vote on potential share dilution. However, a segment of the community views the current dip as a buying opportunity, emphasizing NuScale's NRC-certified SMR technology as crucial for addressing the escalating energy demands of AI data centers and future global power needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss.</li><li>The study showed that participants reported reductions in food-related thoughts and cravings</li><li>Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026.</li></ul>Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) surged 36% in premarket trading on Thursday after the company announced encouraging Phase 1a results for CRB-913, an oral CB1 inverse agonist targeting chronic obesity.At the time of writing, <a href="https://stocktwits.com/symbol/CRBP">CRBP</a> was among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Results Of The Study</h2>Corbus Pharma said that the single-and multiple-ascending dose study showed that CRB-913 was safe and well-tolerated across all doses, with no serious treatment-emergent adverse events reported. Gastrointestinal issues were minimal, and daily neuropsychiatric assessments remained negative, indicating no signs of suicidality, depression, or anxiety.Participants reported reductions in food-related thoughts and cravings, highlighting early behavioral effects alongside weight reduction. Pharmacokinetic analysis confirmed that CRB-913 is suitable for once-daily oral dosing.Building on the early results, Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026. This next stage will further explore optimal dosing and continue evaluating safety, tolerability, and efficacy over a longer period.CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. Unlike earlier drugs in this class that raised neuropsychiatric safety concerns, CRB-913 is designed for limited brain penetration to reduce those risks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘extremely’ bullish from ‘neutral’ a day earlier, accompanied by ‘extremely high’ message volumes.One user expressed optimism about the CANYON-1 study.<stembedurl>https://stocktwits.com/LuigiDurante/message/638840548</stembedurl>Year-to-date, the stock has declined nearly 15%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-appears-set-to-retest-200-dma-last-time-it-did-its-rebound-didn-t-endure/cLIxBZBREnI">MSFT Stock Appears Set To Retest 200-DMA – Last Time It Did, Its Rebound Didn’t Endure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal?

Corbus Pharmaceuticals said its Phase 1a study showed CRB-913 was safe and well-tolerated at all doses, with no serious adverse events reported.

Equity

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat...

B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share estimates for Corbus Pharmaceuticals in a report released...

What is B. Riley's Forecast for CRBP FY2029 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors...

Research Analysts Issue Forecasts for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Corbus Pharmaceuticals in a research note issued to investors...

Royal Bank Of Canada Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00

Royal Bank Of Canada reduced their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an "outperform" rating on the stock in a research report on Thursday...

Corbus Pharmaceuticals (NASDAQ:CRBP) Announces Earnings Results, Misses Expectations By $0.10 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.90) EPS for the quarter, missing the consensus...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average rating of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings...

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CRBP
Corbus Pharmaceuticals Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News

CRBPCorbus Pharmaceuticals Holdings Inc